Anat CohenDayag - Compugen President CEO, Director
| CGEN Stock | USD 1.59 0.02 1.24% |
CEO
Dr. Anat CohenDayag, Ph.D., was named Director, President and Chief Executive Officer for Compugen Ltd. effective February 10, 2014. Dr. Anat CohenDayag joined Compugen in 2002 as Director of Diagnostics, a position she held until 2005 at which time she became Vice President Diagnostic Biomarkers, a position she held until January 2007. From January 2007 until November 2008, Dr. CohenDayag served as Compugens Vice President, Biomarkers and Drug Targets, at which point she was appointed Vice President, Research and Development. In June 2009, Dr. CohenDayag was appointed, together with Mr. Martin Gerstel, as coChief Executive Officer of Compugen. In March 2010, upon Mr. Gerstels election as Chairman of the Board of Directors, Dr. CohenDayag was appointed as Compugens President and CEO. Prior to joining Compugen, she was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. CohenDayag served as a scientist at the RD department of Orgenics Ltd since 2014.
| Age | 57 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | Azrieli Center, Holon, Israel, 5885849 |
| Phone | 972 3 765 8585 |
| Web | https://cgen.com |
Compugen Management Efficiency
The company has return on total asset (ROA) of (0.0304) % which means that it has lost $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1584) %, meaning that it created substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.16. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Compugen's Asset Turnover is very stable compared to the past year.Similar Executives
| Found 10 records | CEO Age | ||
| Gilmore ONeill | Editas Medicine | 60 | |
| Yaacov Yanay | Pluri Inc | 53 | |
| Yehiel Tal | Collplant Biotechnologies | 72 | |
| Michael Brigham | ImmuCell | 63 | |
| Gilmore MD | Editas Medicine | 60 | |
| Pnina Fishman | Can Fite Biopharma | 76 | |
| Ofer CPA | Evogene | 58 | |
| Michel Detheux | Iteos Therapeutics | 57 | |
| Steven MD | Sana Biotechnology | 54 | |
| JD Esq | Annexon | 56 | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0304 |
Compugen Leadership Team
Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alberto Sessa, Chief Officer | ||
| Rivka Schwartz, Vice Discovery | ||
| Henry MD, Senior Officer | ||
| Zurit Levine, VP of Research and Discovery | ||
| Eran Ophir, Chief Officer | ||
| Michelle MD, Chief Officer | ||
| Anat CohenDayag, President CEO, Director | ||
| Yvonne Naughton, Head Communications | ||
| David CPA, Chief Officer | ||
| Dorit Amitay, Vice Resources | ||
| Eran Dor, General Secretary | ||
| Oliver Froescheis, Sr Devel | ||
| Pierre Ferre, Vice Development | ||
| Yaron MBA, Senior Solutions |
Compugen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0304 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.51) % | ||||
| Current Valuation | 30.6 M | ||||
| Shares Outstanding | 89.54 M | ||||
| Shares Owned By Insiders | 5.37 % | ||||
| Shares Owned By Institutions | 14.96 % | ||||
| Number Of Shares Shorted | 1.32 M | ||||
| Price To Earning | (4.86) X |
Pair Trading with Compugen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.Moving together with Compugen Stock
Moving against Compugen Stock
| 0.73 | VCYT | Veracyte | PairCorr |
| 0.67 | VERA | Vera Therapeutics | PairCorr |
| 0.66 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.41 | VCEL | Vericel Corp Ord | PairCorr |
| 0.37 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.03 | Revenue Per Share 0.48 | Quarterly Revenue Growth 3.461 | Return On Assets (0.03) | Return On Equity (0.16) |
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.